Group 1: Financial Performance - In Q3 2025, the company achieved an operating revenue of 622.11 million yuan, representing a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders reached 38.4 million yuan, with a year-on-year increase of 31.41% [2] - The net profit excluding non-recurring items grew by 36.83% [2] Group 2: Business Collaboration and Expansion - Following its integration into the General Technology Group, the company has accelerated business collaboration with medical institutions, successfully opening 138 accounts across 25 provinces by the end of September 2025 [2] - The company has enhanced its creditworthiness, leading to broader financing channels and a noticeable decrease in financing costs [2] Group 3: Pharmaceutical Operations - The company is one of three national wholesale enterprises for narcotic and psychotropic drugs, holding regional wholesale qualifications in 15 provinces, with a sales network covering 31 provinces and autonomous regions [3] - The company has a competitive advantage in narcotic drug distribution in regions such as Sichuan, Chongqing, Guizhou, Qinghai, and Tibet [3] Group 4: Retail Operations - By the end of September 2025, the company operated retail pharmacies across 22 provinces, municipalities, and autonomous regions, including 210 community health pharmacies and 832 DTP prescription pharmacies [3] - The company plans to strengthen its retail omnichannel construction and enhance its nationwide network layout, focusing on multi-dimensional marketing services and patient management systems [3]